Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pantera

Explore full profile

Large-scale actinium-225 production for targeted cancer therapy

Mol, BelgiumFounded 2022Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2024
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Pantera and the history behind them.

About Pantera

PanTera is a biotechnology company dedicated to advancing cancer treatment through the development and application of radiopharmaceuticals. Our mission is to bring new hope to cancer patients by enabling the widespread use of precision therapies that target and treat tumors effectively.

At PanTera, we recognize the significant potential of radiopharmaceuticals in transforming cancer care. These innovative therapies combine radioactive isotopes with targeting molecules to deliver precise, localized radiation to cancer cells, minimizing damage to healthy tissue. By harnessing the power of radiopharmaceuticals, we aim to improve treatment outcomes and enhance the quality of life for patients.

Our focus is on developing and optimizing radiopharmaceuticals that can be used in a variety of cancer types. We work closely with researchers, clinicians, and industry partners to advance the science of radiopharmaceuticals and bring these therapies to a broader range of patients. Our team of experts is committed to overcoming the technical and logistical challenges associated with the production, distribution, and administration of radiopharmaceuticals.

PanTera's approach is grounded in a deep understanding of cancer biology and the unique properties of radiopharmaceuticals. We employ advanced technologies and rigorous scientific methods to design and test new therapies, ensuring their safety and efficacy. Our goal is to create a portfolio of radiopharmaceuticals that can be tailored to the specific needs of individual patients, providing personalized and effective treatment options.

In addition to our research and development efforts, PanTera is dedicated to educating healthcare professionals and patients about the benefits of radiopharmaceuticals. We believe that increased awareness and understanding of these therapies will lead to greater adoption and improved patient access. By collaborating with key stakeholders in the healthcare community, we aim to build a supportive ecosystem for the use of radiopharmaceuticals in cancer treatment.

PanTera is driven by a passion to make a meaningful difference in the lives of cancer patients. Our commitment to innovation, scientific excellence, and patient-centered care guides our work and inspires us to push the boundaries of what is possible in cancer treatment.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
Mol, Belgium
Employees
63
Open positions
3
Dealroom signal
92.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Oncology, Radiotherapy, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Sep 2024 $102M $409M Eurazeo · PMV · Korys · Kurma Partners ↗
DEBTDebt Sep 2024 $37M — Belfius · KBC ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Pantera website traffic

Latest recorded traffic for Pantera is 1.6K monthly website visits, up 135.3% over the last three months. Pantera's team grew 26% over the past year.

Latest monthly visits1.6K 3-month web change+135.3% 1-year team growth+26%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • EQT Life Sciences
  • Eurazeo
  • PMV
  • Korys
  • Kurma Partners
  • SFPIM
  • IBA Worldwide

Series B and later2 investors entered at this stage

  • Belfius
  • KBC
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇧🇪 Belgium90.2%
🇳🇱 Netherlands4.9%
🇫🇷 France2.4%
🇨🇦 Canada2.4%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pantera on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pantera’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.